FrancophonIA/ELRC3.0 huggingface dataset:
English: Vogt-Koyanagi-Harada syndromeh
Maltese: Kemm jingħata YERVOY
English: Very common diarrhoeac, vomiting, nausea
Maltese: Komuni ħafna dijareaċ, rimettar, nawseja
English: Not known pericardial disordersj Vascular disorders Common hypertension hypertension
Maltese: Mhux komuni effużjoni plewrali Disturbi gastro-intestinali
English: Further information on Nuceiva can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/nuceiva.
Maltese: ema.europa.eu/medicines/human/EPAR/nuceiva.
English: Nuceiva (botulinum toxin type A) EMA/249428/2019
Maltese: Nuceiva (tossina tal-botulinju tat-tip A) EMA/249428/2019
English: Other information about Nuceiva
Maltese: Informazzjoni oħra dwar Nuceiva
English: Thirty days after treatment, 87% (205 out of 235) of adults who received Nuceiva had either mild or no vertical lines between the eyebrows, compared with 83% (202 out of 244) of patients who received another medicine containing botulinum toxin type A and 4% (2 out of 48) of patients who were given placebo.
Maltese: Tletin jum wara l-kura, 87% (205 minn 235) tal-adulti li rċevew Nuceiva kellhom jew ftit li xejn linji vertikali bejn il-ħuġbejn jew xejn, meta mqabbla ma' 83% (202 minn 244) tal-pazjenti li rċevew mediċina oħra li kien fiha t-tossina tal-botulinju tat-tip A u 4% (2 minn 48) tal-pazjenti li ngħataw plaċebo.
English: The effectiveness of treatment was measured using a standard 4-point scale, called glabellar line scale (GLS), where 0 = no lines, 1 = mild, 2 =moderate and 3 = severe.
Maltese: L-effettività tal-kura tkejlet bl-użu ta' skala standard ta' 4 punti, imsejħa l-iskala tal-linja glabellari (GLS), fejn 0 = l-ebda linja, 1 = ħafif, 2 = moderat u 3 = sever.
English: Nuceiva (botulinum toxin type A)
Maltese: Nuceiva (tossina tal-botulinju tat-tip A)
English: Serious side effects include drooping eyelids, immune responses (when the body's defence system produces antibodies against the botulinum toxin which stop the medicine from working), spread of the toxin to other parts of the body (which may lead to muscle weakness, difficulty breathing or swallowing, and constipation), development or worsening of disorders affecting the muscles and nerves, and hypersensitivity (allergic) reactions.
Maltese: Effetti sekondarji serji jinkludu għajnejn fil-ħofra, risponsi immunitarji (meta s-sistema ta' difiża tal-ġisem tipproduċi antikorpi kontra t-tossina tal-botulinju li twaqqaf il-mediċina milli taħdem), tifrix tat-tossina għal partijiet oħra tal-ġisem (li tista' twassal għal dgħufija fil-muskoli, diffikultà biex tieħu nifs jew tibla', u stitikezza), żvilupp jew deterjorament ta' disturbi li jaffettwaw il-muskoli u n-nervituri, u reazzjonijiet (allerġiċi) ta' sensittività eċċessiva.
English: The active substance in Nuceiva, botulinum toxin type A, is produced by the bacterium Clostridium botulinum.
Maltese: Is-sustanza attiva f'Nuceiva, it-tossina tal-botulinju tat-tip A, hija prodotta mill-batterju Clostridium botulinum.
English: What are the risks associated with Nuceiva?
Maltese: X'inhuma r-riskji assoċjati ma' Nuceiva?
English: The medicine is injected in 5 different places above and between the eyebrows.
Maltese: Il-mediċina tiġi injettata f'5 postijiet differenti fuq u bejn ilħuġbejn.
English: Nuceiva contains the active substance botulinum toxin type A.
Maltese: Nuceiva fih is-sustanza attiva tossina tal-botulinju tat-tip A.
English: Nuceiva has been shown to make the vertical lines between the eyebrows less noticeable in a main study involving 540 adults with moderate or severe vertical lines that affected their mood or caused symptoms of anxiety or depression.
Maltese: Nuceiva ntwera li jagħmel il-linji vertikali bejn il-ħuġbejn inqas notevoli fi studju ewlieni li involva 540 adult b'linji vertikali moderati jew severi li affettwaw il-burdata tagħhom jew ikkawżaw sintomi ta' ansjetà jew depressjoni.
English: Nuceiva is at least as effective as another medicine containing botulinum toxin type A and more effective than placebo in adults with moderate to severe vertical lines between the eyebrows.
Maltese: Nuceiva huwa mill-inqas effettiva daqs mediċina oħra li fih it-tossina tal-botulinju tat-tip A u aktar effettiv mill-plaċebo f'adulti b'linji vertikali minn moderati sa severi bejn il-ħuġbejn.
English: Further data on the long-term safety of the medicine will be collected post-marketing.
Maltese: Aktar data dwar is-sigurtà fit-tul tal-mediċina se tinġabar wara t-tqegħied fis-suq.
English: The toxin reduces the release of acetylcholine, a chemical messenger that causes muscle contraction.
Maltese: It-tossina tnaqqas ir-rilaxx ta' aċetilkolina, messaġġier kimiku li jikkawża l-kontrazzjoni talmuskoli.
English: As for all medicines, data on the use of Nuceiva are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Nuceiva hija ssorveljata kontinwament.
English: It is used in adults less than 65 years of age who have moderate to severe facial lines and in whom those lines are having a significant psychological impact.
Maltese: Tintuża f'adulti li għandhom inqas minn 65 sena u għandhom linji severi f'wiċċhom u li fuqhom dawn il-linji qed ikollhom impatt psikoloġiku sinifikanti.
English: In the study, Nuceiva was compared with another medicine containing botulinum toxin type A and placebo (a dummy treatment).
Maltese: Fl-istudju, Nuceiva tqabbel ma' mediċina oħra li kien fiha t-tossina tal-botulinju tat-tip A u l-plaċebo (kura finta).
English: Nuceiva must not be used in people with diseases affecting the muscles, such as myasthenia gravis or Eaton-Lambert syndrome, and those who have an infection or inflammation at the planned site of injection.
Maltese: Nuceiva ma għandux jintuża f'persuni b'mard li jaffettwa l-muskoli, bħal myasthenia gravis jew issindrome ta' Eaton-Lambert, u dawk li għandhom infezzjoni jew infjammazzjoni fis-sit ippjanat ta' injezzjoni.
English: If no side effects are experienced during the initial treatment, the injections can be repeated after at least 3 months.
Maltese: Jekk matul il-kura inizjali ma jkun hemm l-ebda effett sekondarju, l-injezzjonijiet jistgħu jiġu ripetuti wara mill-inqas 3 xhur.
English: How is Nuceiva used?
Maltese: Kif jintuża Nuceiva?
English: Nuceiva is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows.
Maltese: Nuceiva hija mediċina użata biex temporanjament ittejjeb id-dehra tal-linji vertikali bejn il-ħuġbejn meta wieħed ikemmex moħħu.
English: For the full list of side effects of Nuceiva, see the package leaflet.
Maltese: Aktar informazzjoni dwar Nuceiva tinstab fis-sit web talAġenzija:
English: Invented name Strength Pharmaceutical form Route of administration Immediate Packaging
Maltese: Qawwa Għamla farmaċewtika
English: EMA/CHMP/472738/2013 EMEA/H/C/002679
Maltese: EMA/472738/2013 EMEA/H/C/002679
English: The full EPAR for Ultibro Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Glycopyrronium is a muscarinic receptor antagonist.
Maltese: Glycopyrronium huwa antagonist tar-riċettur muskariniku.
English: Ultibro Breezhaler is a medicine that contains two active substances, indacaterol (85 micrograms) and glycopyrronium (43 micrograms).
Maltese: Ultibro Breezhaler huwa mediċina li fiha żewġ sustanzi attivi, idacaterol (85 mikrogramma) u glycopyrronium (43 mikrogramma).
English: Indacaterol is a long-acting beta-2 agonist.
Maltese: Indacaterol huwa agonist tal-beta-2 li jaġixxi fit-tul.
English: The reduction in the rate of exacerbations was 10 to 12% higher with Ultibro Breezhaler than with tiotropium and glycopyrronium.
Maltese: It-tnaqqis fir-rata ta' aggravamenti kien ta' 10 sa 12 % ogħla b'Ultibro Breezhaler milli b'tiotropium u glycopyrronium.
English: Ultibro Breezhaler has been studied in two main studies involving a total of 2,667 patients with COPD.
Maltese: Ultibro Breezhaler ġie studjat f'żewġ studji ewlenin li jinvolvu total ta' 2,667 pazjent b'COPD.
English: It works by attaching to beta-2-adrenergic receptors found in the muscles of many organs including the airways of the lungs.
Maltese: Jaġixxi billi jeħel mar-riċetturi adrenerġiċi ta' beta-2 misjuba fil-muskoli ta' diversi organi inkluż il-passaġġi tal-arja tal-pulmuni.
English: This summary was last updated in 09/2013.
Maltese: Is-sommarju ġie aġġornat l-aħħar fi: 09-2013.
English: This is a summary of the European public assessment report (EPAR) for Ultibro Breezhaler.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Ultibro Breezhaler.
English: Other information about Ultibro Breezhaler
Maltese: Informazzjoni oħra dwar Ultibro Breezhaler
English: Ultibro Breezhaler also increased FEV1 by 70 ml more than indacaterol alone and 90 ml more than glycopyrronium alone.
Maltese: Ultibro Breezhaler żied ukoll FEV1 b'70 ml aktar minn indacaterol waħdu u 90 ml aktar minn glycopyrronium waħdu.
English: A risk management plan has been developed to ensure that Ultibro Breezhaler is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jassigura li Ultibro Breezhaler jintuża bl-aktar mod sigur possibbli.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ultibro Breezhaler on 19 September 2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Ultibro Breezhaler fil-19 ta' Settembru 2013.
English: Muscarinic receptor antagonists and long-acting beta-2-adrenergic agonists are commonly combined in the management of COPD.
Maltese: B'mod komuni, l-antagonisti tar-riċetturi muskariniċi u l-agonisti adreniġiċi ta' beta-2 fit-tul jiġu kkombinati fil-ġestjoni tas-COPD.
English: The effects of Ultibro Breezhaler when used to relieve symptoms of COPD were clinically meaningful.
Maltese: L-effetti ta' Ultibro Breezhaler meta jintużaw biex itaffu s-sintomi ta' COPD kienu klinikament sinifikanti.
English: Why is Ultibro Breezhaler approved?
Maltese: Għal xiex ġie approvat Ultibro Breezhaler?
English: Ultibro Breezhaler is available as capsules containing a powder for inhalation and can only be obtained with a prescription.
Maltese: Ultibro Breezhaler huwa disponibbli bħala pilloli li fihom trab li jittieħed man-nifs u jista' jinkiseb mingħajr riċetta.
English: Regarding its safety, Ultibro Breezhaler is comparable to indacaterol and glycopyrronium used as separate medicines.
Maltese: Fir-rigward tas-sigurtà tiegħu, Ultibro Breezhaler jista' jitqabbel ma' indacaterol u glycopyrronium użati bħala mediċini separati.
English: In the second study the average increase in FEV1 was 140 ml more with Ultibro Breezhaler treatment than with treatment with fluticasone and salmeterol.
Maltese: Fit-tieni studju, iż-żieda medja f'FEV1 kienet ta' 140 ml aktar bil-kura ta' Ultibro Breezhaler milli bil-kura b'fluticasone u salmeterol.
English: The active substances in Ultibro Breezhaler, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing in COPD.
Maltese: Is-sustanzi attivi f'Ultibro Breezhaler, indacaterol u glycopyrronium, jaħdmu b'modi differenti biex iwessgħu l-passaġġi tal-arja u jtejbu t-teħid tan-nifs fis-COPD.
English: The most common side effects with Ultibro Breezhaler (which may affect more than 1 in 10 people) are upper respiratory tract infections (colds).
Maltese: L-effetti sekondarji l-aktar komuni b'Ultibro Breezhaler (li jistgħu jolqtu aktar minn 1 minn kull 10) huma l-infezzjonijiet fil-parti ta' fuq tal-passaġġ respiratorju (irjiħat).
English: What are the risks associated with Ultibro Breezhaler?
Maltese: X'inhuma r-riskji assoċjati ma' Ultibro Breezhaler?
English: For the full list of all side effects reported with Ultibro Breezhaler, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Ultibro Breezhaler, ara l-fuljett ta' tagħrif.
English: While one study compared the effects of Ultibro Breezhaler with those of placebo (a dummy inhalation), or indacaterol or glycopyrronium alone, the other study compared Ultibro Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD.
Maltese: F'pazjenti b'funzjoni tal-fwied severament imnaqqsa, Ultibro Breezhaler għandu jintuża biss wara valutazzjoni tal-benefiċċji/riskji bir-reqqa.
English: It is taken at the same time each day using the Ultibro Breezhaler device.
Maltese: Jittieħed fl-istess ħin kuljum permezz tal-apparat ta' Ultibro Breezhaler.
English: EMEA/H/C/666
Maltese: EMEA/H/C/666 RAPPORT TAL-VALUTAZZJONI
English: Medicinal product no longer authorised©EMEA 2007
Maltese: Prodott mediċinali li m'għadux awtorizzat©EMEA 2007
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ACOMPLIA EPAR summary for the public
Maltese: PUBBLIKA EWROPEW (EPAR) ACOMPLIA Sommarju ta' l-EPAR għall-pubbliku
English: ACOMPLIA is a medicine containing the active substance rimonabant.
Maltese: ACOMPLIA hija mediċina li fiha s-sustanza attiva rimonabant.
English: The active substance in ACOMPLIA, rimonabant, is a cannabinoid receptor antagonist.
Maltese: Is-sustanza attiva f'ACOMPLIA, rimonabant, hija antagonist tar-riċettur kannabinojde.
English: What is ACOMPLIA?
Maltese: X'inhi ACOMPLIA?
English: Caution should be used when taking ACOMPLIA with some medicines, such as ketoconazole or itraconazole (anti-fungal medicines), ritonavir (used in HIV infection), or telithromycin or clarithromycin (antibiotics).
Maltese: Meta ACOMPLIA tittieħed ma' xi mediċini, bħalma huma, ketoconazole jew itraconazole (mediċini anti-fungali), ritonavir (użat f'infezzjoni HIV), jew telithromycin jew clarithromycin (antibijotiċi), għandha tintuża l-kawtela.
English: ACOMPLIA is used together with diet and exercise to treat adult patients:
Maltese: ACOMPLIA tintuża flimkien ma' dieta u eżerċizzju biex tikkura pazjenti adulti:
English: What is the risk associated with ACOMPLIA?
Maltese: X'inhu r-riskju assoċjat ma' ACOMPLIA?
English: Why has ACOMPLIA been approved?
Maltese: Għaliex ġiet approvata ACOMPLIA?
English: The company will use specific databases to monitor ACOMPLIA's side effects, especially those linked to the nervous system.
Maltese: Il-kumpanija se tuża databases speċifiċi biex tissorvelja l-effetti sekondarji ta' ACOMPLIA, speċjalment dawk marbuta mas-sistema nervuża.
English: The European Commission granted a marketing authorisation valid throughout the European Union for ACOMPLIA to sanofi-aventis on 19 June 2006.
Maltese: Il-Kummissjoni Ewropea tat l-awtorizzazzjoni għat-tqegħid fis-suq għal ACOMPLIA valida fl-Unjoni Ewropea kollha lil sanofi-aventis fid-19 ta' Ġunju 2006.
English: Four studies of ACOMPLIA as a help to stop smoking were also carried out in over 7,000 patients, comparing it with placebo, and measuring the effect of the medicine given for 10 weeks (one year in one of the studies) on smoking cessation, and on relapses in the following year.
Maltese: Saru ukoll erba' studji ta' ACOMPLIA bħala għajnuna biex jieqaf it-tipjip f'aktar minn 7,000 pazjent, u qabbluha ma' plaċebo, u kejlu l-effett tal-mediċina mogħtija għal 10 ġimgħat (sena f'wieħed mill-istudji) fuq it-twaqqif tat-tipjip, u fuq rikaduti fis-sena segwenti.
English: Four studies of ACOMPLIA in overweight and obese patients were carried out, involving almost 7,000 patients, whose weight at the start of the studies was on average 94 to 104 kg. One study looked more particularly at patients with abnormal levels of blood fat, and one at patients with type 2 diabetes.
Maltese: Saru erba' studji ta' ACOMPLIA f'pazjenti b'piż żejjed u piż eċċessiv, li involvew kważi 7,000 pazjent, li l-piż tagħhom fil-bidu ta' l-istudji kien medja ta' 94 sa 104kg.
English: How has ACOMPLIA been studied?
Maltese: Kif ġiet studjata ACOMPLIA?
English: Patients who experience symptoms of depression should speak to their doctor and may need to stop treatment.
Maltese: Pazjenti li jesperjenzaw sintomi ta' depressjoni għandhom ikellmu lit-tabib tagħhom u jistgħu jeħtieġu li jwaqqfu l-kura.
English: • who are overweight (with a BMI greater than or equal to 27 kg/m²) and also have other risk factors,
Maltese: • Li għandhom piż żejjed (b' BMI akbar minn jew daqs 27kg/m²) u li għandhom ukoll fatturi ta' riskju oħra, bħal ma huma dijabete tip 2 u dislipidimja (livelli mhux normali ta' xaħmijiet fid-demm tagħhom).
English: It acts by blocking a specific type of receptor, the cannabinoid type 1 (CB1) receptors.
Maltese: Hija taħdem billi timblokka tip speċifiku ta' riċettur, ir-riċetturi kannabinojde (CB1) tip 1.
English: After one year, all patients who received ACOMPLIA lost more weight than those who received placebo: they lost on average 4.9 kg more than placebo, except in the study in diabetic patients, where the difference in the weight loss was 3.9 kg.
Maltese: Wara sena, il-pazjenti kollha li rċievew ACOMPLIA tilfu aktar piż milli dawk li rċievew plaċebo: tilfu medja ta' 4.9kg aktar minn plaċebo, ħlief fl-istudju f'pazjenti dijabetiċi, fejn id-differenza fit-telf tal-piż kienet 3.9kg.
English: During the studies, the most common side effects with ACOMPLIA (seen in more than 1 patient in 10) were nausea (feeling sick) and infections of the upper respiratory tract.
Maltese: Waqt l-istudji, l-aktar effetti sekondarji komuni b'ACOMPLIA (dehru f'aktar minn pazjent 1 minn kull 10) kienu nawżja (dardir) u infezzjonijiet tal-passaġġ respiratorju tan-naħa ta' fuq.
English: It is available as white, teardropshaped tablets.
Maltese: Hija tiġi bħal pilloli bojod f'forma ovali.
English: The effects of ACOMPLIA were first tested in experimental models before being studied in humans.
Maltese: L-effetti ta' ACOMPLIA kienu l-ewwel ittestjati f'mudelli sperimentali qabel ma ġew studjati filbnedmin.
English: Other information about ACOMPLIA:
Maltese: Tagħrif ieħor dwar ACOMPLIA:
English: Which measures are being taken to ensure the safe use of ACOMPLIA?
Maltese: X'miżuri qed jittieħdu biex jassiguraw l-użu sigur ta' ACOMPLIA?
English: EMA/43198/2016 EMEA/H/C/000475
Maltese: EMA/43198/2016 EMA/H/C/000475
English: The full EPAR for Levitra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Other information about Levitra:
Maltese: Informazzjoni oħra dwar Levitra:
English: The active ingredient of Levitra, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Maltese: Is-sustanza attiva f'Levitra, il-vardenafil, hi parti minn grupp ta' mediċini magħruf bħala inibituri fosfodjesterażi tat-tip 5 (PDE5) (phosphodiesterase type 5 (PDE5) inhibitors).
English: Levitra is a medicine that contains the active substance vardenafil.
Maltese: Levitra huwa mediċina li fiha s-sustanza attiva vardenafil.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levitra on 6 March 2003.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Levitra valida fl-Unjoni Ewropea kollha fis-6 ta' Marzu 2003.
English: The recommended dose of Levitra is 10 mg, taken about 25 to 60 minutes before sexual activity.
Maltese: Id-doża rakkomandata ta' Levitra hi ta' 10 mg, meħuda madwar 25 sa 60 minuta qabel l-attività sesswali.
English: This document is a summary of the European public assessment report (EPAR) for Levitra.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Levitra.
English: Levitra tablets were compared with placebo (a dummy treatment) in four main studies including a total of 2,431 men with erectile dysfunction aged 20 to 83 years.
Maltese: Il-pilloli Levitra tqabblu ma' plaċebo (kura finta) f'erba' studji ewlenin li kienu jinkludu total ta' 2,431 raġel b'disfunzjoni erettili ta' bejn l-20 u t-83 sena.
English: Two additional main studies compared orodispersible tablets with placebo in 701 men aged 21 to 84 years
Maltese: Żewġ studji ewlenin addizzjonali qabblu l-pilloli orodispersibbli mal-plaċebo f'701 irġiel ta' bejn il-21 u l-84 sena.
English: What is the risk associated with Levitra?
Maltese: X'inhu r-riskju assoċjat ma' Levitra?
English: Why has Levitra been approved?
Maltese: Għaliex ġie approvat Levitra?
English: Levitra must not be taken with ketoconazole and itraconazole (used to treat fungal infections) in men over 75 years of age, or with medicines called ‘HIV protease inhibitors' such as ritonavir or indinavir (used to treat HIV infection).
Maltese: Levitra m'għandux jintuża mal-ketoconazole u l-itraconazole (użati biex jikkuraw infezzjonijiet minn fungi) f'irġiel ta' iktar minn 75 sena, jew ma' mediċini msejħa 'inibituri tal-proteażi tal-HIV' bħarritonavir jew l-indinavir (użati biex jikkuraw infezzjoni tal-HIV).
English: • patients with unstable angina and hereditary eye problems known as ‘retinal degenerative disorders'.
Maltese: • pazjenti li jsofru minn anġina instabbli u problemi ereditarji fl-għajnejn magħrufa bħala ‘disturbi deġenerattivi tar-retina'.
English: In addition, Levitra must not be taken with medicines known as guanylate cyclase stimulators, including riociguat (used to treat pulmonary hypertension [high blood pressure in the lungs]).
Maltese: Barra minn hekk, Levitra ma għandux jittieħed ma' mediċini magħrufa bħala stimulaturi ta' gwanilat ċiklażi (guanylate cyclase), inkluż riociguat (użat biex jikkura ipertensjoni pulmonari [pressjoni għolja tad-demm fil-pulmuni]).
English: During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax.
Maltese: Waqt stimulazzjoni sesswali normali, fil-pene tiġi prodotta s-cGMP li tikkawża r-rilassament fil-muskolu fit-tessut tal-pene li qisu sponża (il-corpora cavernosa).
English: Levitra is used to treat adult men (aged 18 years or over) with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity.
Maltese: Levitra jintuża fil-kura ta' rġiel adulti (minn 18-il sena 'l fuq) b'disfunzjoni erettili (xi kultant imsejħa impotenza), meta ma jkunux jistgħu jilħqu jew iżommu pene iebes (erezzjoni) għal attività sesswali sodisfaċenti.
English: By blocking the breakdown of cGMP, Levitra restores erectile function.
Maltese: Billi jiġi mblukkat it-tkissir tas-cGMP, Levitra jreġġa' l-funzjoni erettili għan-normal.
English: A risk management plan has been developed to ensure that Levitra is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Levitra jintuża bl-aktar mod sigur possibbli.
English: What is Levitra?
Maltese: Għal xiex jintuża Levitra?
English: A starting dose of 5 mg should be considered for patients with mild and moderate liver problems or severe kidney problems.
Maltese: Għandha tiġi kkunsidrata doża tal-bidu ta' 5 mg għal pazjenti bi problemi żgħar u moderati fil-fwied jew bi problemi serji fil-kliewi.
English: The dose of the film-coated tablets may be increased to a maximum of 20 mg or decreased to 5 mg, depending on the effectiveness of treatment and any side effects.
Maltese: Id-doża ta' pilloli miksija b'rita tista' tiżdied sa massimu ta' 20 mg jew titnaqqas sa 5 mg skont l-effikaċja tal-kura u skont leffetti sekondarji.
English: How does Levitra work?
Maltese: X'inhu Levitra?
English: Crospovidone, type A
Maltese: Crospovidone, tip A
English: Via Provinciale Schito 131 80058 Torre Annunziata (NA) Italy
Maltese: Via Provinciale Schito 131 80058 Torre Annunziata (NA) L-Italja
English: Table 1 Immune system disorders Rare:
Maltese: Tabella 1 Disturbi fis-sistema immuni Rari:
English: BLISTER (CALENDAR)
Maltese: FOLJA FOLJA (KALENDARJU)
English: Colloidal anhydrous silica Hypromellose substitution type 2910 (3 mPa·s) Macrogol 4000
Maltese: Hypromellose sostituzzjoni tip 2910 (3 mPa·s) Macrogol 4000
English: Date of latest renewal: 22 May 2017
Maltese: Data tal-ewwel awtorizzazzjoni: 22 Awwissu 2007 Data tal-aħħar tiġdid: 22 Mejju 2017
English: Palpitations, oedema peripheral
Maltese: Palpitazzjonijiet, edima periferali